99% Ribociclib / LEE011 Powder CAS 1211441-98-3
Product Description
| Product name | Ribociclib |
| Appearance | White powder |
| MF | C23H30N8O |
| Assay | 99% |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
Ribociclib for advanced hormone receptor positive, HER2 negative breast cancer - first line ribociclib is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Ribociclib does not currently have Marketing Authorisation in the EU for any indication. Ribociclib is in phase II studies for breast cancer.
Function and Application
Ribociclib is used when the cancer has progressed or has spread to other parts of the body after other treatments.
Ribociclib is given in combination with another cancer medicine such as (Femara) or (Faslodex).
Ribociclib may also be used for purposes not listed in this medication guide.
